FDA Approves Janssen's Tremfya For Treatment Of Adults With Active Psoriatic Arthritis

(RTTNews) - MorphoSys AG (MOR) Tuesday said that its licensee Janssen Research & Development LLC announced the U.S. Food and Drug Administration approval of Tremfya as a treatment for adult patients living with active psoriatic arthritis.

Active PsA is a chronic progressive disease characterized by painful joints and skin inflammation.

As Janssen announced, the approval of Tremfya was based on results from the Phase 3 studies DISCOVER-1 and DISCOVER-2, which evaluated the efficacy and safety of Tremfya in adults with active PsA compared to placebo.

Dr. Malte Peters, Chief Research and Development Officer of MorphoSys, said: "Active psoriatic arthritis is a high burden for patients, causing limited mobility, pain and fatigue. We are very pleased about the FDA approval for Tremfya(R), providing patients with a new treatment option for this debilitating indication."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.